Evaluation of vitrectomy combined preoperative intravitreal ranibizumab and postoperative intravitreal triamcinolone acetonide for proliferative diabetic retinopathy

To explore the treatment efficacy of combination preoperative intravitreal ranibizumab (IVR) and postoperative triamcinolone acetonide (IVTA) in patients undergoing pars plana vitrectomy (PPV) for proliferative diabetic retinopathy (PDR). A retrospective comparative study was performed on 128 eyes who had PDR underwent PPV. Patients received a single PPV were assigned to Group A. Those with IVR B. C combined IVTA. Intraoperative findings, changes mean best-corrected visual acuity (BCVA) adverse events, retrospectively evaluated at 6-month follow-up. The incidences iatrogenic breaks, severe intraoperative bleeding, using long-term internal tamponade agents, recurrent vitreous hemorrhage (VH), duration surgery statistically significantly less B than BCVA better Groups A, respectively, 1 month after surgery. 3-month C. incidence high intraocular pressure (IOP) higher first week. There no significant differences exudative retinal detachment choroidal among three groups. In PDR, reduced occurrence complications, IVTA can improve outcome.